Euroopa Liit - eesti - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. vt lõigud 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Euroopa Liit - eesti - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastilised ained - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastilised ained - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Euroopa Liit - eesti - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - muud dermatoloogilised preparaadid - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Eesti - eesti - Ravimiamet

renascience pharma limited - tsefepiim - süste-/infusioonilahuse pulber - 1000mg 1g 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

biofrontera bioscience gmbh - 5-aminolevuliinhappe vesinikkloriid - keratosis, actinic; carcinoma, basal cell - antineoplastilised ained - ravi actinic keratoos kerge kuni mõõduka raskusastmega näo ja peanaha (olsen hinne 1, 2; vt punkt 5. 1) ja väli cancerization täiskasvanutel. ravi pealiskaudne ja/või kühmulised basaalrakuline kartsinoom sobi kirurgiline ravi tõttu võimalik ravi-seotud haigestumuse ja/või kehv kosmeetiline tulemus täiskasvanutel.

Euroopa Liit - eesti - EMA (European Medicines Agency)

leadiant gmbh - chenodeoxycholic happega - xanthomatosis, cerebrotendinous; metabolism, inborn errors - vere ja maksa ravi - chenodeoxycholic hape on näidustatud kaasasündinud vigadest esmane sapphapete sünteesi tõttu sterooli 27 hüdroksülaasi puudulikkus (esitades kui cerebrotendinous xanthomatosis (ctx)) imikutel, lastel ja noorukitel vanuses 1 kuu kuni 18 aastat ja täiskasvanute.

Eesti - eesti - Ravimiamet

gufic biosciences limited - amfoteritsiin - süstelahuse lüofilisaat - 50mg 1tk

Eesti - eesti - Ravimiamet

incyte biosciences distribution b.v. - ruksolitiniib - kreem - 15mg 1g 60g 1tk

Eesti - eesti - Ravimiamet

gufic biosciences limited - amfoteritsiin - infusioonilahuse pulber - 50mg 1tk